Keros Therapeutics (KROS) Current Leases (2019 - 2025)

Keros Therapeutics has reported Current Leases for 7 years, with the latest figure at $2.4 million in Q4 2025.

• For the quarter ending Q4 2025, Current Leases rose 21.74% year-over-year to $2.4 million; the trailing twelve-month figure through Dec 2025 stood at $2.4 million (up 21.74% YoY), and the FY2025 full-year result was $2.4 million, up 21.74% from the prior year.
• Current Leases for Q4 2025 stood at $2.4 million, up from $2.3 million in the prior quarter.
• The five-year high for Current Leases was $2.4 million in Q4 2025, with the low at $436000.0 in Q1 2021.
• Historically, Current Leases has averaged $1.2 million across 5 years, with a median of $944500.0 in 2022.
• Annual changes were most pronounced in 2022 — Current Leases plunged 47.22% — and 2024, when it soared 203.93%.
• Keros Therapeutics' Current Leases stood at $862000.0 in 2021, then sank by 47.22% to $455000.0 in 2022, then jumped by 120.88% to $1.0 million in 2023, then soared by 96.82% to $2.0 million in 2024, then gained by 21.74% to $2.4 million in 2025.
• The last three Current Leases figures came in at $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.2 million (Q2 2025), per Business Quant data.